The work addresses one of the most stubborn problems in modern oncology: translating the spectacular success of CAR T cell therapy in blood cancers into solid tumors. Since the first CAR T products received regulatory approval, patients with certain leukemias and lymphomas have benefited from engineered immune cells that can seek out and destroy malignant cells bearing a specific molecular marker. Solid tumors, however, have proven far more difficult targets. They deploy hostile microenvironments, suppressive signaling pathways, and heterogeneous surface antigens that blunt the activity of infused cells. Breast cancer, the leading cause of cancer-related mortality globally, exemplifies these challenges, and the study’s authors frame their work as a direct response to this unmet clinical need.

The choice of target antigen is central to the strategy. Mucin 1 is a large, heavily glycosylated protein that normally lines the apical surfaces of epithelial tissues, where it plays protective roles. In tumor cells, however, glycosylation patterns break down, producing a hypoglycosylated, tumor-associated form of MUC1 that is exposed in ways the normal protein is not. This aberrant presentation makes MUC1 an attractive target for T cell-based therapies, because the abnormal form is largely absent from normal tissues, potentially widening the therapeutic window. The team, led by researchers at the Siriraj Center of Research Excellence for Cancer Immunotherapy at Mahidol University’s Faculty of Medicine Siriraj Hospital, set out to establish both the clinical relevance of MUC1 and the superiority of a fourth-generation receptor design against it.

To establish that relevance, the investigators turned to The Cancer Genome Atlas, a large public repository of genomic and clinical data. Their analysis revealed that high MUC1 expression in breast cancer is associated with reduced overall survival and reduced disease-free survival, positioning MUC1 not merely as a target but as a potential prognostic biomarker that could help identify patients with aggressive disease. The genomic signal was then corroborated at the protein level. Using immunohistochemical staining on patient tissue samples, the researchers found that 57 of 59 breast cancer samples, or 96.6 percent, were positive for MUC1. High MUC1 expression was also confirmed across breast cancer cell lines used in the laboratory experiments, ensuring that the preclinical models faithfully reflected the antigen landscape of human tumors.

With the target validated, the team constructed and compared three CAR designs. Second-generation receptors, the workhorse of approved therapies, combine an antigen-binding domain with a single intracellular costimulatory module, typically CD28 or 4-1BB, fused to the CD3 zeta signaling chain. Third-generation receptors add a second costimulatory domain in an effort to amplify activation. Fourth-generation receptors go further, incorporating an additional genetic payload, often encoding a cytokine or other immune-enhancing factor, that is expressed upon antigen engagement, effectively turning the engineered cell into a localized delivery system for immune stimulation. The αM.CAR4 construct paired an anti-MUC1 single-chain variable fragment, the HMFG2 sequence generously provided by Professor John Maher, with this augmented signaling architecture.

The comparative evaluation began at baseline, where the fourth-generation cells displayed immunophenotypes broadly comparable to those of the second- and third-generation counterparts, indicating that the added complexity had not fundamentally altered the cells’ resting state. The differences emerged dramatically after antigen exposure. When the engineered cells encountered MUC1-expressing tumor cells, the αM.CAR4 T cells demonstrated significantly the highest proliferation among the three designs while simultaneously exhibiting the lowest exhausted phenotype, a statistically significant advantage at the p less than 0.05 threshold. T cell exhaustion, a dysfunctional state marked by inhibitory receptor upregulation and loss of effector function, is a major cause of CAR T failure in solid tumors, making this resilience particularly noteworthy.

Cytotoxic performance told a similar story. The fourth-generation cells required markedly lower doses to achieve higher levels of tumor cell killing, a difference significant at the p less than 0.01 level, suggesting that each αM.CAR4 cell packs greater lethal capacity per encounter. Consistent with this, the cells produced significantly higher levels of cytotoxic effector proteins, the molecular weapons, including granzymes and perforin, that engineered T cells deploy to punch holes in tumor cell membranes and trigger programmed cell death. In three-dimensional spheroid models, which better mimic the dense architecture of real tumors than flat cell cultures, the αM.CAR4 cells induced rapid spheroid destruction, again reaching statistical significance at p less than 0.05. Together, these assays paint a picture of a receptor design that not only survives antigen stimulation but converts it into sustained, potent anti-tumor activity.

The implications extend in two directions. Clinically, the findings support MUC1 expression as a potential prognostic biomarker in breast cancer, offering a molecular handle for risk stratification that could complement existing markers. Therapeutically, the results argue that fourth-generation CAR architecture may be the key to unlocking MUC1-directed immunotherapy for solid tumors, where earlier generations have struggled. Because the tumor-associated form of MUC1 is largely absent from normal tissues, the approach may also carry a favorable safety profile compared with targets shared between healthy and malignant cells, though on-target off-tumor effects against epithelial tissues will require careful evaluation in future studies.

The researchers are careful to position this work as a foundation rather than a finished therapy. Their summary explicitly states that αM.CAR4 T cells represent a promising alternative strategy for breast cancer immunotherapy and that the findings support further development and evaluation of MUC1-targeting CAR T cells in pre-clinical and clinical studies. The road from laboratory bench to approved treatment is long, involving manufacturing optimization, safety pharmacology, dose escalation, and ultimately randomized clinical trials. Yet the convergence of near-universal MUC1 expression in patient samples, a clear survival correlation from genomic data, and demonstrable functional superiority of the fourth-generation design gives the field a coherent rationale for advancing this approach.

The study also reflects a broader international and collaborative effort. The work was conducted by teams spanning Mahidol University’s Siriraj Hospital in Bangkok, including the Division of Head-Neck and Breast Surgery, the Department of Pathology, and the Department of Immunology, in partnership with Kumamoto University in Japan, where co-author Seiji Okada leads the Division of Hematopoiesis at the Joint Research Center for Human Retrovirus Infection. Many of the investigators are members of the Thailand Hub of Talents in Cancer Immunotherapy, supported by the National Research Council of Thailand, with additional funding from Mahidol University and Siriraj Research Fund. As breast cancer continues to claim lives worldwide despite advances in surgery, chemotherapy, and targeted agents, engineered immune cells capable of recognizing the aberrant molecular signature of malignancy, and sustaining their attack where earlier designs falter, offer a compelling glimpse of where cancer immunotherapy may be headed next.

Subject of Research: Development of fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced immunotherapy of breast cancer

Article Title: Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer

Article References: Supimon, K., Sangsuwannukul, T., Sawasdee, N., Choomee, K., Natungnuy, K., Nganrungreung, S., Tripatara, P., Jirawatnotai, S., Sa-nguanraksa, D., Warnnissorn, M., Thuwajit, C., Okada, S., Junking, M., & Yenchitsomanus, P.-T. (2026). Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04557-y

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04557-y

Keywords: breast cancer, CAR T cells, chimeric antigen receptor, mucin 1, cancer immunotherapy, MUC1, fourth-generation CAR, T cell exhaustion, tumor immunology, prognostic biomarker, immunotherapy, solid tumors

The therapy belongs to a class of treatments known as CAR T-cell immunotherapy. The process begins with the collection of a patient’s own T cells, the immune system’s specialized killers. In the laboratory, those cells are genetically modified so that they carry engineered receptors capable of recognizing and binding to specific molecules on the surface of cancer cells. Once reprogrammed, the cells are expanded into large numbers and returned to the patient, where they circulate, seek out their targets and attack. The technique has already produced striking results in certain blood cancers, including leukemia and lymphoma, where engineered immune cells have driven durable remissions in patients who had exhausted every other option.

Translating that success to solid tumors such as colorectal cancer has proved far more difficult. Solid tumors are physically dense, immunologically hostile environments that engineered cells struggle to infiltrate and survive in. They deploy molecular defenses that suppress or redirect immune attacks, and they present a fundamental targeting problem: researchers must find a molecule that is abundant on cancer cells but scarce on healthy tissue, so that the therapy attacks the tumor without destroying vital organs. That targeting challenge has been one of the central obstacles holding back CAR T-cell therapy for the many cancers that form solid masses rather than circulating freely in the blood.

The CU Anschutz team believes it has found a way around that obstacle by aiming at two targets at once. The first is B7-H3, a protein found on the surface of most colorectal tumors and, importantly, on a wide range of other cancers as well. Researchers at several institutions have been investigating B7-H3 as a potential cancer target precisely because of its broad presence across tumor types. The second target is IL-8, a signaling protein that helps promote tumor growth, inflammation and the spread of cancer through the body. By simultaneously targeting B7-H3 and the IL-8 pathway, the engineered cells are designed to strike both the tumor itself and one of the biological systems it uses to grow and evade immune destruction. The researchers hope that this two-pronged strategy will give the engineered cells a better chance of overcoming the defenses that have limited earlier attempts to treat solid tumors with CAR T-cell therapy.

The dual-target design also reflects a deliberate strategic choice about which patients the therapy could eventually serve. Michael Verneris, MD, professor of pediatric oncology at CU Anschutz and program co-leader of Tumor-Host Interactions at the CU Anschutz Cancer Center, said the team wanted to move away from highly narrow approaches. “This is a very different way of thinking about how we treat cancer,” Verneris said. “We wanted to find targets that are present across many different cancers rather than developing a therapy that would only apply to a small number of patients.” If the trial demonstrates that the approach is safe and effective, the researchers say it could eventually be tested against other cancers in which these pathways play a role, including some breast, lung and ovarian cancers.

Christopher Lieu, MD, professor of medical oncology at CU Anschutz and associate director of clinical research at the CU Anschutz Cancer Center, is leading the trial. He framed the therapy as a potential alternative to the blunt instruments of conventional treatment. “Chemotherapy extends survival and helps cure people,” Lieu said. “At the same time, it’s like dropping an unguided bomb on a disease. Maybe you hit your target, but you are going to do a lot of collateral damage.” He is hoping the therapy, which has proven effective in animal models, will produce far longer-lasting results than current options typically deliver. “Immunotherapy gives us the opportunity to direct the immune system toward the cancer and potentially produce a much more durable response,” he said. The goal, he added, is not measured in months but in years.

The urgency behind the trial is underscored by troubling epidemiological trends. Colorectal cancer is increasingly affecting younger adults, with rates among people under 45 rising substantially over the past several decades while researchers continue to investigate the reasons behind the shift. For patients whose disease advances despite standard therapies, options narrow rapidly. Currently, only a small percentage of patients with colorectal and other gastrointestinal cancers qualify for certain forms of immunotherapy, because those treatments depend on specific tumor biomarkers that many patients do not have. Because B7-H3 is present in a much larger proportion of colorectal cancers, the researchers hope their approach could ultimately be applicable to a far broader patient population. “Given the number of patients we are seeing, we need new approaches,” Lieu said. But he and his colleagues are careful to note that the first step is determining whether the therapy is safe in people and whether it can effectively attack cancer in the human body, as it has in animal models.

The path from concept to clinical trial also highlights the structural advantages of the CU Anschutz campus, which brings together the university’s health professional schools, Children’s Hospital Colorado, UCHealth University of Colorado Hospital and the Gates Biomanufacturing Facility within easy walking distance of one another. The experimental cells for the trial will be manufactured at the Gates Biomanufacturing Facility, meaning the entire pipeline, from basic research to cell production to patient treatment, exists on a single campus. “The whole spectrum is right here,” Verneris said. “If we didn’t have the Gates Institute, we wouldn’t be able to make our own cells. This could have remained an interesting idea. Instead, it has become a clinical trial that could have a real impact on patients.” Philanthropic support has been essential to reaching this point, Verneris noted, because trials of this kind are expensive and private donations made it possible to move the therapy from the laboratory into patients. “We are incredibly grateful to the donors who have helped make this possible,” he said.

For the patients who enroll, the trial represents something that advanced colorectal cancer currently offers in short supply: a chance at a treatment designed to last. If the engineered cells can safely navigate the hostile terrain of solid tumors and dismantle the pathways that colorectal cancers use to grow and spread, the trial could open a new front against one of the most common and increasingly prevalent cancers, and potentially against several others beyond it. The FDA’s clearance now allows that hypothesis to be tested in the place it matters most, in the bodies of the patients the therapy was designed for.

Subject of Research: A first-in-human clinical trial of dual-target CAR T-cell immunotherapy for advanced colorectal cancer

Article Title: FDA clears CU Anschutz clinical trial using engineered immune cells to fight colorectal cancer

Article References: FDA clears CU Anschutz clinical trial using engineered immune cells to fight colorectal cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR T-cell therapy, colorectal cancer, FDA clearance, clinical trial, immunotherapy, B7-H3, IL-8, solid tumors, CU Anschutz, pediatric cancer, engineered immune cells, Gates Biomanufacturing Facility

The modern immunotherapy era began with high-dose interleukin-2, which demonstrated that immune activation could produce long-lasting tumor regression in a small proportion of patients with metastatic melanoma and renal cell carcinoma. The arrival of antibodies against CTLA-4, followed by inhibitors of the PD-1 and PD-L1 pathways, transformed that early proof of concept into a central pillar of cancer treatment. These drugs work by interrupting inhibitory signals that restrain T cells. CTLA-4 blockade mainly enhances T-cell priming in lymphoid tissues, while PD-1 or PD-L1 inhibition can restore the function of exhausted T cells within the tumor microenvironment. The results have included unprecedented survival improvements and long-term remission for some people with melanoma, non-small cell lung cancer, kidney cancer, and other malignancies. Yet the benefits remain uneven, and many tumors either never respond or eventually evolve around immune attack.

One of the most important newer targets is LAG-3, an inhibitory receptor found on activated T cells, regulatory T cells, B cells, and natural killer cells. LAG-3 can bind major histocompatibility complex class II molecules and suppress T-cell receptor signaling, proliferation, and production of immune-stimulating cytokines such as interleukin-2 and interferon-gamma. Its expression is particularly prominent in exhausted T cells, suggesting that it may help maintain a dysfunctional immune state inside tumors. The first approved LAG-3-directed therapy, relatlimab, is used with the PD-1 inhibitor nivolumab in advanced or metastatic melanoma. In the RELATIVITY-047 trial, the combination extended median progression-free survival to 10.1 months, compared with 4.6 months for nivolumab alone, and increased the objective response rate from 32.6 percent to 43.1 percent. Severe treatment-related adverse events occurred in 18.9 percent of patients receiving the combination, versus 9.7 percent with nivolumab alone—higher, but generally less frequent than with CTLA-4 and PD-1 combinations.

The LAG-3 story also illustrates why the next generation of immunotherapy will not be a simple succession of universal replacements for older drugs. Relatlimab has shown limited activity in patients whose disease has already progressed on checkpoint inhibitors, with an objective response rate of about 12 percent in one reported setting. Established PD-1 resistance often reflects multiple biological failures, including defective antigen presentation, exclusion of T cells from tumors, altered interferon signaling, and the emergence of immune-suppressive cell populations. Blocking one additional checkpoint may therefore be insufficient once resistance is entrenched. Still, the nivolumab-relatlimab combination has generated interest in earlier disease. Studies in melanoma have reported encouraging pathological responses before surgery, including a 57 percent pathological complete response rate in one neoadjuvant cohort and an 80 percent four-year event-free rate. Other LAG-3 strategies include fianlimab, the immune-activating fusion protein eftilagimod alpha, and bispecific antibodies designed to target both PD-1 and LAG-3 in a single molecule.

Perhaps the most powerful shift is the expansion of immunotherapy beyond the organ where a cancer began. Tissue-agnostic treatment relies on biological features shared across different tumor types, particularly defective DNA mismatch repair and high microsatellite instability. Mismatch repair proteins normally correct small copying errors made during DNA replication. When this system fails, tumors accumulate insertions, deletions, and other mutations, producing abnormal proteins known as neoantigens. These neoantigens can make cancer cells more visible to T cells, increasing the likelihood that PD-1 blockade will work. Deficient mismatch repair can result from inherited mutations associated with Lynch syndrome or from acquired epigenetic silencing, such as methylation of the MLH1 promoter. Clinicians can identify the phenotype using immunohistochemistry, polymerase chain reaction, or next-generation sequencing, allowing treatment decisions to be based on tumor biology rather than anatomical origin.

Tumor mutational burden, which measures the number of somatic mutations per megabase of tumor DNA, offers a related but less reliable signal. The underlying theory is straightforward: more mutations should create more potential neoantigens and therefore more targets for immune recognition. Clinical studies have indeed associated higher mutational burden with improved responses in diseases such as lung cancer and melanoma. However, not every mutation produces an antigen, and not every antigen is displayed effectively by a tumor cell. Measurements also vary between sequencing platforms, differ between tissue and blood samples, and can be distorted by tumor heterogeneity. As a result, mutational burden has not proved consistently dependable as a standalone predictor. A particularly striking subgroup is formed by tumors carrying pathogenic POLE proofreading mutations. These cancers can be ultramutated, densely infiltrated by lymphocytes, and exceptionally responsive to immunotherapy, even when their microscopic appearance suggests aggressive disease.

The clinical consequences of these biomarkers are becoming visible in major trials. In the KEYNOTE-158 study, pembrolizumab produced a response rate of approximately 29 percent in tumors classified as having high mutational burden, compared with 6 percent in tumors without that designation. Responses in mismatch repair-deficient or microsatellite-instability-high cancers were often remarkably durable. In advanced colorectal cancer, the phase 3 KEYNOTE-177 trial showed that first-line pembrolizumab produced a median overall survival of 77.5 months, compared with 36.7 months for chemotherapy, with five-year survival rates of 54.8 percent and 44.2 percent, respectively. The CheckMate-8HW trial further indicated that combining nivolumab with ipilimumab could outperform chemotherapy and nivolumab alone in selected patients, producing a two-year progression-free survival of 72 percent versus 14 percent with chemotherapy. In locally advanced mismatch repair-deficient rectal cancer, neoadjuvant dostarlimab has produced an especially dramatic signal: all 41 patients reported in one study achieved a clinical complete response and entered a watch-and-wait program without immediate surgery or chemoradiotherapy.

That result points toward one of the most provocative possibilities in oncology: replacing automatically scheduled surgery with response-adapted care. The concept is not yet established broadly, and longer follow-up plus prospective randomized evidence remain essential. Nevertheless, highly immunogenic tumors may eventually be managed by treating first, measuring the depth of response, and reserving surgery for residual or recurrent disease. Similar discussions are emerging in melanoma, head and neck cancer, and lung cancer. The approach would represent a profound change in the traditional sequence of cancer care, potentially preserving organs and reducing the complications of major operations. It also raises demanding technical questions. A clinical complete response does not always mean every malignant cell has disappeared, and microscopic residual disease may be difficult to detect with imaging or endoscopy. Future trials will need sensitive molecular monitoring, carefully defined retreatment strategies, and long-term surveillance to determine which patients can safely avoid surgery.

Checkpoint inhibitors are also being combined with established treatments to reshape the tumor environment before immune cells arrive. Chemotherapy can kill cancer cells and release tumor antigens, effectively providing raw material for immune priming. Antiangiogenic drugs can alter abnormal tumor blood vessels, reduce immune suppression, and improve T-cell access. In unresectable liver cancer, atezolizumab plus bevacizumab and the durvalumab-tremelimumab regimen have improved outcomes compared with the former standard, sorafenib. Median overall survival has reached roughly 16.4 to 19.2 months with atezolizumab and bevacizumab, compared with 13.4 to 13.8 months with sorafenib. The choice between regimens can depend on bleeding risk and the safety of vascular endothelial growth factor inhibition. In extensive-stage small-cell lung cancer, adding atezolizumab or durvalumab to platinum-etoposide chemotherapy has delivered the first major advance in decades, extending survival beyond the short-lived responses traditionally produced by chemotherapy alone.

The next wave reaches beyond soluble antibodies and conventional drug combinations. Bispecific antibodies and T-cell engagers can bind a tumor-associated molecule with one arm and a T-cell receptor component with the other, physically bringing immune cells into contact with malignant cells. Antibody-drug conjugates attach potent cytotoxic payloads to tumor-targeting antibodies, concentrating chemotherapy-like activity near cancer cells while potentially limiting exposure elsewhere. Adoptive cell therapies are being adapted for solid tumors through tumor-infiltrating lymphocytes, chimeric antigen receptors, and engineered T-cell receptors. TIL therapy uses a polyclonal population of tumor-reactive lymphocytes expanded from a patient’s own tumor, while CAR and TCR technologies genetically reprogram T cells to recognize selected targets. Engineered cytokines seek to preserve the immune-stimulating effects of interleukin therapies without reproducing their severe systemic toxicity. Personalized vaccines, particularly those directed against patient-specific neoantigens, aim to initiate or strengthen an immune response tailored to the mutations carried by an individual tumor.

Together, these advances reveal an emerging strategy rather than a single miracle treatment. The future of solid-tumor immunotherapy will depend on matching the right immune mechanism to the right biological context, deciding when combinations are more valuable than sequential treatment, and identifying resistance before tumors become clinically obvious. Immune-related toxicities—including pneumonitis, myocarditis, neurological complications, and permanent endocrine damage—remain a major concern as treatment moves into earlier-stage disease, where many patients may already be cured by surgery or other therapies. People with active brain metastases, poor performance status, or a need for corticosteroids have also been underrepresented in pivotal trials. The field is therefore converging on precision immuno-oncology: biomarker testing, response-adapted treatment, engineered molecules, cellular products, and increasingly individualized vaccines. If researchers can make immune attacks more selective and resistance more predictable, therapies once effective only for a minority could become durable, organ-preserving treatments across a much broader range of solid cancers.

CAR therapy works by equipping an immune cell with a synthetic receptor that recognizes a chosen molecule on the surface of a cancer cell. The receptor typically contains an antibody-derived binding region, known as a single-chain variable fragment, or scFv, connected to signaling components that activate the engineered cell. In CAR-T-cell therapy, this design enables T cells to identify and kill malignant cells. CAR macrophages use the same broad principle but assign the task to macrophages, immune cells naturally adapted to engulf cellular material through phagocytosis. Once activated, a macrophage can surround a target, internalize it and digest it in an intracellular compartment. Yet solid tumors present a difficult environment for these cells. They may be poorly recruited into the tumor mass, become functionally suppressed after arrival or fail to recognize cancer cells that express only small amounts of the target antigen. A therapy dependent on one receptor-antigen interaction can therefore lose effectiveness when tumors alter or reduce that molecular marker.

The researchers’ solution was to combine the target recognition and engulfment machinery of CAR macrophages with the mobility and destructive chemistry of neutrophils. Neutrophils are among the first immune cells recruited to sites of infection or tissue damage. They respond rapidly to chemical gradients, migrating toward signals released by inflamed or injured tissue. They can also deploy neutrophil extracellular traps, or NETs: web-like structures composed largely of DNA and associated proteins that immobilize threats outside the cell. During this process, and through other antimicrobial responses, neutrophils release reactive oxygen species. These chemically reactive molecules can damage biological structures, although their effects must normally be tightly controlled to avoid harming healthy tissue. By fusing neutrophils with CAR macrophages, the investigators sought to create a single cell-like therapeutic system that could combine directed tumor recognition, active phagocytosis, chemokine-guided movement and neutrophil-derived attack mechanisms. The resulting S-CAR-Ms were not simply macrophages carrying a second drug; they were designed as an integrated cellular platform whose functions could reinforce one another.

A central finding was that the fused cells accumulated in tumors more efficiently than conventional CAR macrophages. The reported explanation is chemokine-driven migration, a process in which immune cells detect concentration gradients formed by signaling proteins released from tumors and surrounding tissues. Neutrophils are highly responsive to these gradients, and their migratory behavior appears to remain functionally important after integration with CAR macrophages. This matters because the number of engineered cells administered to a patient is not the same as the number that reaches the malignant tissue. Solid tumors can contain dense extracellular matrix, abnormal blood vessels, regions of low oxygen and immunosuppressive cells that collectively form a physical and biochemical barrier. A cell that recognizes cancer in a laboratory dish may therefore perform poorly if it cannot reach the tumor or move through it. The enhanced accumulation of S-CAR-Ms suggests that neutrophil properties may help overcome one of the earliest bottlenecks in cell therapy: getting therapeutic cells out of the circulation and into the disease site in sufficient numbers.

Once inside tumors, S-CAR-Ms appeared to exploit a second advantage inherited from their neutrophil component. The release of NETs and reactive oxygen species increased the exposure of phosphatidylserine, or PtdSer, on tumor cells. PtdSer is a phospholipid normally concentrated on the inner surface of the plasma membrane. When a cell is stressed, damaged or undergoing programmed cell death, PtdSer can become exposed on the outer membrane, where it acts as an “eat me” signal for phagocytic cells. Macrophages recognize this signal through receptors and bridging molecules, including the MerTK pathway. The investigators found that the neutrophil-derived activity made more tumor-cell material visibly available to this clearance system. In practical terms, the S-CAR-Ms could identify cancer through their engineered scFv receptor when the selected antigen was present, but they could also recognize and engulf damaged tumor material through the PtdSer–MerTK route. That dual recognition system is important because it reduces dependence on a single molecular label.

The two pathways may also create a self-reinforcing cycle inside the tumor. CAR recognition can bring the engineered macrophage into close contact with an antigen-bearing cancer cell, while neutrophil-derived reactive molecules can injure nearby tumor cells and expose PtdSer. The macrophage can then engulf cellular debris through its natural clearance machinery, even when that debris contains little of the original CAR target. This distinction addresses a major problem in cancer immunotherapy known as antigen escape. Tumors are genetically diverse populations rather than uniform masses. If treatment eliminates cells with abundant target antigen, pre-existing or newly selected variants with low levels of that antigen may survive and repopulate the tumor. A therapy that combines antigen-specific recognition with a broader damage-associated signal could continue to remove cells that would otherwise slip past the CAR receptor. The study reports that S-CAR-M treatment triggered antigen spreading, meaning that the immune response expanded from the original targeted antigen to additional tumor-associated targets released or revealed as cancer cells were destroyed. This process could make the attack less vulnerable to the tumor’s molecular evolution.

The researchers tested the approach in both syngeneic and xenograft mouse models, two experimental systems that answer different questions. Syngeneic models use tumor cells and immune cells from genetically compatible animals, allowing investigators to study treatment in the presence of an intact immune system. Xenograft models implant human or otherwise foreign tumor cells into mice, often in settings designed to permit tumor growth despite immune incompatibility. Across these models, the study reports that a single dose of S-CAR-Ms reduced tumor burden, limited the spread of cancer to distant sites and helped prevent recurrence. Those findings are particularly notable because recurrent disease and metastasis are responsible for much of cancer’s lethality, while many experimental treatments show their strongest effects only against established primary tumors. However, the mouse results cannot yet establish whether the cells will behave similarly in people. Human tumors vary widely in their chemokine signals, antigen expression and tissue architecture, and immune-cell fusion products must also be manufactured consistently and tested for safety.

The design nevertheless highlights why solid tumors have remained a difficult frontier for engineered-cell therapy. In blood cancers, therapeutic cells can circulate through a relatively accessible compartment and encounter malignant cells directly. Solid tumors are more like hostile ecosystems, with abnormal vasculature, low nutrient and oxygen levels, high interstitial pressure and suppressive signals that can blunt immune function. Macrophages are naturally abundant in many tumors, but tumor-associated macrophages are often reprogrammed into states that support cancer growth, tissue remodeling or immune suppression. Engineering them with a CAR can redirect their recognition, but it does not automatically solve problems of trafficking or local activity. Neutrophils offer a different set of biological tools, yet their inflammatory molecules can also cause collateral tissue injury if unleashed without adequate control. The therapeutic promise of S-CAR-Ms therefore depends not only on their ability to kill tumor cells, but also on whether their activity can remain localized, whether they persist for an appropriate period and whether their manufacture avoids unwanted activation or inconsistent cell states.

The next steps will require detailed safety and translational studies before the approach can be considered for patients. Scientists will need to determine how the fused cells are produced, how stable the fusion state remains, how long the cells survive after infusion and whether they can be controlled or eliminated if severe inflammation develops. The balance between tumor-damaging reactive oxygen species and injury to healthy tissue will be especially important. Researchers will also need to test whether the method works across different cancer types and target antigens, and whether the chemokine signals that attract neutrophil-integrated cells are present in human tumors at useful levels. Even with those questions unresolved, the study offers a striking example of immune engineering moving beyond the idea of giving one cell one receptor and one job. By combining receptor-guided recognition, neutrophil-like migration and oxidative damage with macrophage-mediated clearance and antigen spreading, S-CAR-Ms are intended to confront cancer as a moving, heterogeneous target. In mice, that integrated strategy produced a broader response than conventional CAR macrophages; whether it can translate into a safe treatment for solid tumors will determine the significance of the advance.

Subject of Research: Neutrophil-integrated syncytial chimeric antigen receptor macrophages for cancer immunotherapy

Article Title: Neutrophil-integrated syncytial CAR macrophage for cancer immunotherapy

Article References: Tian, T., Zhao, S., Tian, T. et al. “Neutrophil-integrated syncytial CAR macrophage for cancer immunotherapy.” Nature Immunology (2026). https://doi.org/10.1038/s41590-026-02615-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41590-026-02615-2

Keywords: cancer immunotherapy, CAR macrophages, neutrophils, solid tumors, phagocytosis, antigen escape, antigen spreading, neutrophil extracellular traps

Conventional approaches to treating lung metastasis face substantial hurdles, primarily due to the complexity of metastatic niches and the immune suppressive environments tumors often establish. Chimeric Antigen Receptor (CAR) T-cell therapies have shown promise against certain blood cancers but struggle against solid tumors, including lung metastases. Macrophages, as tissue-resident immune cells known for their plasticity and phagocytic capabilities, present a promising alternative platform for CAR engineering. Unlike T cells, macrophages can infiltrate tumor masses and modulate the immune microenvironment, making them potent effectors against solid tumor lesions.

Central to this breakthrough is the delivery of CAR-encoding messenger RNA (mRNA) directly to macrophages within the lung tissue, circumventing the complexities and costs associated with ex vivo cell manipulation and expansion. The researchers developed a delivery system based on small extracellular vesicles (sEVs), nanoscale lipid bilayer-enclosed particles naturally secreted by cells, which are well-known for their biocompatibility, stability, and inherent ability to cross biological barriers to facilitate intercellular communication. By loading sEVs with mRNA encoding the CAR construct, the team was able to efficiently transfect lung macrophages in situ, thereby generating CAR macrophages where they are needed most.

This approach addresses several critical limitations faced by current CAR therapies. First, it eliminates the need for personalized cell collection and manufacturing—a time-consuming and expensive process. Second, it enables repeated dosing, allowing the modulation of therapeutic intensity over time. Third, in situ generation minimizes systemic toxicities by concentrating the engineered immune effectors within the tumor-bearing organ, reducing off-target effects.

From a mechanistic perspective, the study meticulously characterized how sEV-delivered mRNA is taken up by tissue macrophages and translated into functional CAR proteins. Advanced imaging techniques confirmed that these CAR macrophages actively engaged and phagocytosed lung metastatic tumor cells expressing the target antigen. Furthermore, transcriptomic and proteomic analyses revealed upregulation of pro-inflammatory and anti-tumoral pathways, suggesting that the CAR macrophages not only eliminate cancer cells directly but also reshape the immunosuppressive tumor microenvironment to favor endogenous immune responses.

Preclinical murine models of metastatic lung cancer served as a vital platform to test the therapeutic efficacy of the mRNA-sEV system. Mice treated with sEV-CAR-mRNA exhibited significantly reduced tumor burden and prolonged survival compared with control groups. Notably, the recurrence rate after primary tumor resection was also markedly decreased, highlighting the potential of this strategy to diminish minimal residual disease and prevent relapse—a persistent challenge in oncology.

An intriguing aspect of the research lies in the modularity and versatility of the system. By altering the sequence of the CAR mRNA, sEVs can be programmed to target a broad spectrum of tumor antigens, potentially allowing rapid adaptation to different cancer types or the emergence of tumor antigen escape variants. This adaptability holds immense promise for personalized medicine, offering a platform technology that can be tailored to individual patients’ tumor profiles without the delays of bespoke cell engineering.

The safety profile of this approach was addressed through comprehensive toxicological assessments. Unlike viral vector-based gene therapies, mRNA-based delivery via sEVs exhibits transient expression, reducing the risks of insertional mutagenesis or long-term off-target effects. Additionally, the natural origin and biocompatibility of sEVs likely minimize immune reactions against the delivery vehicle itself, an often overlooked but significant hurdle in gene therapy.

The implications of this advancement extend beyond lung metastasis to a wider landscape of metastatic and recurrent cancers. The lung is a common site for secondary tumor seeding from various primary cancers such as breast, colon, and melanoma. Therefore, an effective, minimally invasive immunotherapeutic tool that can generate potent anti-tumor macrophages directly at these metastatic sites could transform clinical outcomes for countless patients worldwide.

Technically, the production and purification of therapeutic sEVs loaded with CAR mRNA were optimized through state-of-the-art engineering, including electroporation for mRNA loading and size exclusion chromatography for high-purity vesicle isolation. The research team also explored modifications to the vesicle surface to enhance tissue targeting and uptake efficiency, leveraging ligands and antibodies that recognize markers enriched on lung-resident macrophages.

This study fundamentally challenges the current paradigm of cell-based immunotherapies being exclusively ex vivo constructs. In situ generation of engineered immune effectors redefines the therapeutic landscape, shifting focus toward biomimetic delivery systems that integrate seamlessly within the patient’s immune ecosystem. Furthermore, the reduction in manufacturing bottlenecks and logistic complications associated with cell therapies may democratize access to these potent treatments globally.

Future directions will undoubtedly explore clinical translation pathways, including scaling sEV production under good manufacturing practice (GMP) conditions and conducting detailed pharmacokinetic and pharmacodynamic studies in larger animal models. Human trials will be essential to validate safety and efficacy, but the preclinical data are already compelling.

Moreover, it remains an open question how tumor heterogeneity and the evolving immunosuppressive milieu in patients might influence the effectiveness of in situ CAR macrophage generation. The interplay between engineered macrophages and other immune cells, including T cells and dendritic cells, will be critical to understand for harnessing synergistic anti-tumor responses.

In conclusion, the innovative approach delineated by Xiao and colleagues represents a significant leap forward in immuno-oncology. By delivering CAR-encoding mRNA via small extracellular vesicles directly to lung-resident macrophages, they have pioneered a platform for in situ immune reprogramming with robust anti-cancer efficacy against metastatic lesions and tumor recurrence. This strategy holds transformative potential not only for lung metastases but also for the broader challenge of treating solid tumors across multiple organs. As research progresses, this elegant fusion of synthetic biology, immunology, and nanotechnology could pave the way for next-generation cancer therapies marked by precision, safety, and accessibility.

Subject of Research:
Article Title:
Article References:

Xiao, Y., Zhu, T., Chen, Z. et al. Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat Commun 16, 7166 (2025). https://doi.org/10.1038/s41467-025-62506-2

Image Credits: AI Generated

In typical scenarios, producing CAR T-cells—engineered immune cells designed to target and destroy cancer—can be an arduous and time-consuming endeavor. The traditional methods often necessitate a complicated and resource-intensive process that spans one to two weeks. As a consequence, this lengthy duration can limit patient access to potentially life-saving treatments. The introduction of an ultra-fast and highly scalable manufacturing platform marks a significant turning point in the field, making it feasible to manufacture CAR T-cell products within a single day. This rapidity not only enhances accessibility but also has the potential to lower associated costs significantly, addressing one of the most pressing barriers to CAR T-cell therapy utilization.

The research led by David Wald, MD, PhD, has reached an important milestone with the application of this novel process. Thus far, 15 lymphoma patients have received CAR T-cell therapy generated from this new platform in ongoing clinical trials at the UH Seidman Cancer Center. The early results have been astonishing, with most participants achieving complete remissions. Such cases imply that a faster production rate does not compromise the efficacy of the treatment but rather enhances it. Moreover, the current findings suggest that the CAR T-products stemming from this innovative approach exhibit a substantially improved toxicity profile compared to their traditional counterparts. This aspect could lead to fewer adverse effects, further solidifying the advantages of this expedited manufacturing process.

In addition to this pioneering abstract, the research team presented another compelling work at the same conference titled “Efficient Cost-Effective Manufacture of a Non-Viral Transposon Based Novel BAFF CAR T for Treatment of B-cell Cancers.” This second abstract emphasizes the development of a CAR T-cell product utilizing a non-viral transposon system designed specifically for the treatment of Hodgkin lymphoma and multiple myeloma. Both forms of CAR T-cell therapy are crucial as they provide alternative treatment options for patients who have shown resistance to standard therapies. The capacity to revolutionize CAR T-cell therapy is pivotal in a landscape where certain cancers remain stubbornly resistant to conventional treatment methodologies.

The significance of this research extends beyond mere technical advancements. With more than 700 cellular therapy products manufactured for clinical trials at the UH Seidman Cancer Center and across the nation, the onsite cellular therapy facility showcases a dedicated pursuit of innovative solutions in cancer treatment. Collaboration with the Case Western Reserve University has further strengthened the center’s position in the realm of regenerative medicine, symbolizing a commitment to advancing patient care through rigorous research and development.

The capabilities embedded within the Wesley Center for Immunotherapy reflect a broader vision for the future of cancer care whereby effective therapies can be made available to a greater number of patients. Beyond the impressive scientific developments, this paradigm shift emphasizes the importance of ensuring accessibility and reducing financial barriers that have historically limited the reach of advanced therapies. The integration of cutting-edge immunotherapy solutions into mainstream cancer treatment plans offers the potential to transform patient outcomes dramatically through faster and more efficient treatment protocols.

Furthermore, Dr. David Wald’s recognition as part of the 2025 class of Senior Members for the National Academy of Inventors underscores the profound impact of his research efforts. This distinction serves as an acknowledgment not only to his innovative research in the immunotherapy field but also to his contributions toward refining and enhancing clinical procedures aimed at improving patient care in oncology. Such accolades inspire future research endeavors and reinforce the ethos of innovation within academic and clinical settings.

At its core, the advances made by the Wesley Center for Immunotherapy in CAR T-cell manufacturing are fundamentally reshaping the treatment landscape for patients battling challenging malignancies. The delicate balance between expedient manufacturing and the retention of therapeutic efficacy is being meticulously navigated, resulting in a breakthrough that holds immense promise for the future of cancer treatment.

In conclusion, the implications of this research extend far beyond the laboratory. By encapsulating the complexities of cell therapy manufacturing within a single-day timeframe, the feasibility of providing timely treatment to patients in critical need has become a tangible reality. As we continue to push the bounds of scientific inquiry and translational research, innovations like these highlight the potential for a brighter future in cancer care, where lifesaving options are swiftly accessible and profoundly effective.

As the field of cellular therapy evolves, the contributions from University Hospitals Seidman Cancer Center and collaborative research efforts signify a shared commitment to transforming the future of oncology. Accelerating the pace of innovation while maintaining a focus on patient-centered care will undoubtedly lead to further advancements, offering new hope to those coping with the challenges of cancer.

Subject of Research: CAR T-cell Therapy Manufacturing Process
Article Title: Breakthrough in CAR T-cell Therapy Manufacturing: A Day May Be All You Need
News Publication Date: [Current Date]
Web References: [Links to relevant studies or articles]
References: [Complete references to the research presented]
Image Credits: [Credits for any images used in the article]

Keywords: CAR T-cell therapy; immunotherapy; cancer treatment; manufacturing process; clinical trials; lymphoma; multiple myeloma; regenerative medicine; University Hospitals Seidman Cancer Center; cell therapy.

Trogocytosis is a complex process that allows immune cells to exchange cell surface molecules, altering the immune response landscape. This exchange involves the physical interaction between two cells, leading to the transfer of membrane components and proteins. In the context of CAR-T cell therapy, which involves genetically modifying T cells to express CAR molecules that target cancer, understanding this transfer could radically change therapeutic approaches. Researchers have historically struggled to elucidate the mechanisms regulating trogocytosis, specifically in how the transfer of integral membrane proteins occurs.

One of the pivotal findings from this new study is that CAR molecules can be transferred from CAR-T cells to other T cells through this process of trogocytosis, challenging prior assumptions that these molecules required specific receptor binding to facilitate transfer. Stefano Barbera, the postdoctoral researcher who is a first and corresponding author of the study, stated that the study indicates that while direct contact between cells is essential, the transfer of these molecules does not depend on corresponding receptors being present on the recipient cells.

This finding is revolutionary as it discloses a potentially new regulatory mechanism for trogocytosis, one that does not follow the classical receptor-ligand interactions that have characterized much of immunological research to date. The research team has demonstrated that more complex, yet undiscovered mechanisms might govern how immune cells exchange components, potentially influencing therapeutic strategies in CAR-T cell therapy.

The implications of this discovery are manifold. Researchers now have the opportunity to invent CAR molecules tailored with specific attributes to either facilitate or inhibit the trogocytosis process. This level of control could be instrumental in refining the therapeutic outcomes of CAR-T cell therapies through comparative studies of CAR molecules with varying trogocytosis capabilities. Furthermore, a major unresolved question remains: how does the extent of trogocytosis in the CAR-T cell therapy context affect overall treatment efficacy or side effects?

Previous theories suggested that the mere presence of corresponding receptors on target T cells was essential for trogocytosis to occur, which this study has directly contradicted. The researchers’ emphasis on the significance of the membrane region surrounding the transferring molecule suggests novel targets for therapeutic intervention aimed at enhancing CAR-T cell effectiveness.

Moreover, understanding the specific dynamics of trogocytosis could lead to a paradigm shift in the development of next-generation CAR therapies. The inherent ability of these engineered T cells to share functional components with native T cells may not only bolster their anti-tumor activity, but also influence the overall immune environment in which tumors reside. Deciphering these mechanisms neatly aligns with ongoing efforts to enhance personalized cancer treatments and improve patient responsiveness.

As this research continues in the future, a deeper investigation into the biological role of CAR trogocytosis is warranted. Researchers hope to establish whether modulation of this process can help ameliorate treatment side effects commonly associated with CAR-T cell therapy—an area that would address a crucial gap in current cancer therapeutics.

In summary, through the lens of this pioneering study, the nuances of immune cell interaction have opened new avenues for enhancing CAR-T cell therapy. The ability to dictate the dynamics of molecule sharing offers researchers exciting possibilities not only for improving efficacy but also for paving the way towards innovative practices in immunotherapy. The ramifications of such understanding could ultimately lead to more robust treatments for patients battling various forms of cancer and opens the door for significant advancements in personalized medicine.

As researchers at Uppsala University delve deeper into CAR-T cell behavior in tumor environments, a broad spectrum of exciting new research avenues emerges. Future investigations could focus on harnessing the principles outlined in this study, testing modified CAR constructs in advanced model systems, and ultimately taking these findings to clinical trials. The scientific community watches closely, eager to see how these findings will translate from bench to bedside in real-world applications.

In conclusion, the study of CAR-T cell trogocytosis represents an intriguing frontier in cancer treatment research. As our comprehension of these mechanisms evolves, it is likely that we will see a significant transformation in therapeutic strategies that harness the immune system’s own tools for defending against cancer. Indeed, the potential for enhanced CAR-T therapies that are more effective and have fewer side effects is a tantalizing prospect.

Subject of Research: Animals
Article Title: Trogocytosis of Chimeric Antigen Receptors between T cells is regulated by their transmembrane domains
News Publication Date: 31-Jan-2025
Web References: DOI Link
References: Barbera S, Schuiling MJA, Sanjaya NA, Pietilä I, Sarén T, Essand M, Dimberg A.
Image Credits: Credit: Mikael Wallerstedt

Keywords: CAR-T cells, immunotherapy, trogocytosis, cancer treatment, Uppsala University, transmembrane domains, immune response, cancer therapy.